Clinical Data

ASCO: Summit reached with China lung data but new climb begins to prove global benefit

BioSpace

"King Keytruda's reign continues," analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics' ivonescimab were revealed at the American Society for Clinical Oncology in Chica

Oncology

Read full story

pharminent June 1, 2026 (Last updated: June 1, 2026)

BioSpace

“King Keytruda’s reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chica

Oncology

Read full story

Related Stories

ASCO: BMS hails “compelling” phase 3 celmod readout

Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers

GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’

You May Have Missed

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

ASCO: Summit reached with China lung data but new climb begins to prove global benefit

Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide